CD79B Antibody (B-4): sc-373808

CD79B Antibody (B-4) is a mouse monoclonal IgM antibody that detects CD79B in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD79B, also known as B29, plays a crucial role in forming B cell antigen receptor complex by pairing with CD79A, which is essential for B cell activation and signaling. CD79B facilitates surface expression of membrane immunoglobulins, such as IgM and IgD, which are vital for antigen recognition and immune response. The cytoplasmic tail of CD79B contains an immuno-receptor tyrosine-based activation motif (ITAM) that initiates downstream signaling pathways upon antigen binding, activating tyrosine kinases that propagate B cell activation signal. CD79B serves as a key player in B cell biology and a significant target for therapeutic interventions in diseases involving B cells, such as certain leukemias and lymphomas. Anti-CD79B antibody (B-4) serves as an invaluable tool for researchers studying B cell function and signaling pathways, providing insights into immune responses and potential disease mechanisms.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD79B Antibody (B-4) References:

1. Igbeta(CD79b) mRNA expression in chronic lymphocytic leukaemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity.  |  Cajiao, I., et al. 2007. Am J Hematol. 82: 712-20. PMID: 17315213
2. Spontaneous mutation in the Cd79b gene leads to a block in B-lymphocyte development at the C' (early pre-B) stage.  |  Shulzhenko, N., et al. 2009. Genes Immun. 10: 722-6. PMID: 19727123
3. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.  |  Kraan, W., et al. 2013. Blood Cancer J. 3: e139. PMID: 24013661
4. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.  |  Yamada, S., et al. 2015. Leuk Lymphoma. 56: 2141-5. PMID: 25347427
5. Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed.  |  Cetin, GO., et al. 2016. Eur Rev Med Pharmacol Sci. 20: 830-6. PMID: 27010137
6. Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.  |  Gurth, M., et al. 2017. Leuk Lymphoma. 58: 979-981. PMID: 27687087
7. Comparative analysis of somatic mutations in MYD88, CD79B, CARD11, and BTK between gastric marginal zone B-cell lymphoma of MALT and diffuse large B-cell lymphoma.  |  Dugge, R., et al. 2024. Ann Hematol. 103: 6057-6058. PMID: 39663255
8. Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.  |  Bibikova, E., et al. 2025. Hematol Oncol. 43: e70008. PMID: 39716442
9. Alternative splicing of CD79a (Ig-alpha/mb-1) and CD79b (Ig-beta/B29) RNA transcripts in human B cells.  |  Hashimoto, S., et al. 1995. Mol Immunol. 32: 651-9. PMID: 7643857
10. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).  |  Moreau, EJ., et al. 1997. Am J Clin Pathol. 108: 378-82. PMID: 9322589

The preferred CD79B antibody is CD79B Antibody (B29/123): sc-53210.